Creative Biolabs has announced a strategic upgrade to its biosimilar development services and CDMO platform, aimed at helping pharmaceutical firms demonstrate that their biosimilar products are "highly similar" or statistically equivalent to reference drugs. The upgrade strengthens the company's capabilities in physicochemical characterization and biological activity comparison, which are critical for regulatory approval.
A chief researcher at Creative Biolabs stated, "At this time, our platform offers an extensive array of physicochemical evaluations, which include primary sequence validation, high-order structure (HOS) analysis, and charge variant analysis. For biological activity, we have established a series of cell-based functional experiments to ensure high consistency with the original drug in terms of binding affinity and downstream signal transduction."
The company's biosimilar development services now cover 20+ popular varieties, including analogues of blockbuster drugs such as Rituximab, Trastuzumab, and Adalimumab. Creative Biolabs addresses discrete technical challenges, such as for the analogue of Bevacizumab, where proprietary high-expression cell line construction technology significantly increases production and optimizes downstream purification processes to remove trace impurities.
To bridge the gap between research and commercialization, Creative Biolabs offers a one-stop CDMO solution providing highly flexible production support. The platform extends beyond monoclonal antibodies to bispecific antibodies, ADC drugs, and viral vectors. Key components include cell line development using CHO and HEK293 platforms with high-yield stable clone screening, upstream process support at bioreactor scales of 50L, 200L, 500L, and 2000L, downstream process involving advanced protein A affinity chromatography, ion exchange, and virus filtration, and quality control with environmental monitoring per GMP standards.
The researcher noted, "Many partners performed well in the pilot stage but encountered yield reduction during scale-up. Our platform addresses this specifically. With our linear scale-up technology and single-use bioreactor systems, we ensure process consistency from initial cloning to commercial GMP production, effectively reducing regulatory risk."
This upgrade positions Creative Biolabs to support global pharmaceutical giants and biotechnology startups in bringing biosimilars to market efficiently. By integrating advanced characterization and scalable manufacturing, the platform aims to lower development costs and accelerate timelines for biosimilar approvals.
